"We are pleased to note that the validity of the Prevenar 13 patent has now been recognized by the Indian Patent Office. Prevenar 13 provides the broadest serotype coverage of any pneumococcal conjugate vaccine available in the world today. Supported by extensive clinical research and real-world experience, each dose of PCV 13 requires 400 different raw materials, 580 manufacturing steps, 678 quality tests and two and a half years to produce. This vaccine was launched in India in 2010. In its multi-dose vial presentation, this vaccine has been included in the expansion of India’s public immunization program in select states under the GAVI funded platform. Pfizer remains committed towards further enhancing access of this vaccine in India, both in the market as well as through partnership with the Government to expand introduction in the public program."